Literature DB >> 28422115

Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis.

Minglin Lin1, Junfei Jin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28422115     DOI： 10.1038/nrclinonc.2017.56

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  16 in total

1.  Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

Authors:  Daniel B Costa; Mark S Huberman
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

2.  Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position.

Authors:  Laurence Albiges; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2017-01-10       Impact factor: 66.675

3.  Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.

Authors:  Sylvain Le Jeune; Gaëtan Des Guetz; Hélène Bihan; Régis Cohen; Jean-Michel Coindre; Jean-Jacques Mourad
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 5.  Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism.

Authors:  Bruno Vergès; Thomas Walter; Bertrand Cariou
Journal:  Eur J Endocrinol       Date:  2014-02-01       Impact factor: 6.664

Review 6.  Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.

Authors:  Gadi Shlomai; Brian Neel; Derek LeRoith; Emily Jane Gallagher
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

Review 7.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 8.  Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Authors:  Adi J Klil-Drori; Laurent Azoulay; Michael N Pollak
Journal:  Nat Rev Clin Oncol       Date:  2016-08-09       Impact factor: 66.675

9.  Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Authors:  George R Simon; Martine Extermann; Alberto Chiappori; Charles C Williams; Mubeena Begum; Rachna Kapoor; Eric B Haura; Roohi Ismail-Khan; Michael J Schell; Scott J Antonia; Gerold Bepler
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

10.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245
View more
  1 in total

1.  Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT-1: Influence on 18 F-FDG PET Uptake.

Authors:  Vijaya L Damaraju; Maral Aminpour; Michelle Kuzma; Philip Winter; Jordane Preto; Jack Tuszynski; Alexander B J McEwan; Michael B Sawyer
Journal:  Clin Transl Sci       Date:  2021-05-03       Impact factor: 4.689
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.